The complex of zinc with N-(5,6-dihydro-4H-1,3-thiazine-2-yl)benzamide
- Authors: Trofimova T.P.1,2, Orlova M.A.1,2, Severin A.V.1, Shalamova E.S.1, Proshin A.N.3, Orlov A.P.1
-
Affiliations:
- Department of Chemistry, M. V. Lomonosov Moscow State University
- D. Rogachev National Research Clinical Center of Pediatric Hematology, Oncology, and Immunology
- Institute of Physiological Active Compounds of Russian Academy of Sciences
- Issue: Vol 67, No 4 (2018)
- Pages: 768-773
- Section: Full Article
- URL: https://journals.rcsi.science/1066-5285/article/view/242472
- DOI: https://doi.org/10.1007/s11172-018-2135-2
- ID: 242472
Cite item
Abstract
A complex of zinc with N-(5,6-dihydro-4H-1,3-thiazin-2-yl)benzamide (L) ligand, LZnCl2, was synthesized for subsequent medical trials. The molar extinction coefficients were determined for LHBr solutions in water and physiological saline, and for LZnCl2 ethanol solution. The ligand stability in various solvents was evaluated and the value of its protonation constant was found for the physiological saline solution, logK = 5.3±0.2. The impossibility of determination of the complex stability constant by the potentiometric titration method was demonstrated. The complex exhibited an insufficient stability in aqueous and physiological saline solutions, but was stable as the solution in alcohol. There was no sorption observed upon the treatment of ligand with hydroxyapatite nanoparticles, which could be a potential carrier for the therapeutic form of LZnCl2, providing additional degrees of freedom for the interaction of ligand with cell membranes and a prolonged action of zinc ions.
About the authors
T. P. Trofimova
Department of Chemistry, M. V. Lomonosov Moscow State University; D. Rogachev National Research Clinical Center of Pediatric Hematology, Oncology, and Immunology
Email: orlova.radiochem@mail.ru
Russian Federation, Bld. 3, 1 Leninskie Gory, Moscow, Russian Federation, 119991; 1 ul. Samory Mashela, Moscow, Russian Federation, 117997
M. A. Orlova
Department of Chemistry, M. V. Lomonosov Moscow State University; D. Rogachev National Research Clinical Center of Pediatric Hematology, Oncology, and Immunology
Author for correspondence.
Email: orlova.radiochem@mail.ru
Russian Federation, Bld. 3, 1 Leninskie Gory, Moscow, Russian Federation, 119991; 1 ul. Samory Mashela, Moscow, Russian Federation, 117997
A. V. Severin
Department of Chemistry, M. V. Lomonosov Moscow State University
Email: orlova.radiochem@mail.ru
Russian Federation, Bld. 3, 1 Leninskie Gory, Moscow, Russian Federation, 119991
E. S. Shalamova
Department of Chemistry, M. V. Lomonosov Moscow State University
Email: orlova.radiochem@mail.ru
Russian Federation, Bld. 3, 1 Leninskie Gory, Moscow, Russian Federation, 119991
A. N. Proshin
Institute of Physiological Active Compounds of Russian Academy of Sciences
Email: orlova.radiochem@mail.ru
Russian Federation, 1 Severnyi proezd, Chernogolovka, Moscow Region, Russian Federation, 142432
A. P. Orlov
Department of Chemistry, M. V. Lomonosov Moscow State University
Email: orlova.radiochem@mail.ru
Russian Federation, Bld. 3, 1 Leninskie Gory, Moscow, Russian Federation, 119991